Vitiligo and Psychodrama Therapy

Summary

The goal of this pilot clinical trial is to assess the effectiveness of psychodramatic psychotherapy in reducing the psychological distress and/or the skin condition in patients with vitiligo.

The main questions it aims to answer are:

1. Is there any improvement in terms of psychological distress in patients with vitiligo participating in a psychodramatic psychotherapy, compared to a control group?
2. Is there any improvement in terms of skin condition in patients with vitiligo participating in a psychodramatic psychotherapy, compared to a control group? Participants in the experimental group will receive the dermatological drug treatment usually recommended for vitiligo, and in addition they will participate in a 6 months psychodramatic psychotherapy.

Researchers will compare the results of the experimental group with the results of a control group including vitiligo patients who will receive the dermatological pharmacological treatment usually recommended for vitiligo and participate in a 6 months program of self-help activities.

Conditions

• Vitiligo

Interventions

BEHAVIORAL

Psychodramatic psychotherapy

The psychodramatic psychotherapy will include a total of 14 meetings during a 6 months period and they will be held in presence (or remotely in case of COVID-19 government restrictions) as follows: * 1 individual motivational interview; * 1 weekly group session lasting 2 hours for 1 month (total 4 meetings); * 1 group session every 15 days lasting 2 hours, for 5 months (total 10 meetings). Patients will also receive the pharmacological treatment usually recommended for vitiligo.

BEHAVIORAL

Self-help activities

The self-help activities will include: * 1 individual motivational interview; * 1 weekly, 2 hours group meeting, for 1 month (total 4 meetings); * 1 group meeting lasting 2 hours every 15 days, for 5 months (total 10 meetings). Patients will also receive pharmacological treatment usually recommended for vitiligo.

Sponsors & Collaborators

• Università degli Studi di Brescia

  collaborator OTHER

• Scuola Psicoterapia Psicodrammatica Brescia

  collaborator UNKNOWN

• Università degli Studi di Trento

  collaborator OTHER

• Azienda Provinciale per i Servizi Sanitari, Provincia Autonoma di Trento

  lead OTHER

Principal Investigators

• Gabriella Pravatà, MD · APSS Trento

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

18 Years

Max Age

55 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2023-11-02

Primary Completion

2024-05-11

Completion

2024-05-11

Countries

• Italy

Study Locations